University of Pittsburgh researchers conclude that while humans can survive months without calories and intermittent fasting may activate beneficial metabolic pathways, current evidence remains insufficient to support widespread adoption of fasting for longevity. They recommend fasting trials only for motivated overweight patients without risk factors like frailty, osteoporosis, or eating disorder history. This measured assessment reflects a critical gap in longevity science: the leap from promising mechanisms to proven interventions. While animal studies consistently show fasting benefits through pathways like autophagy and metabolic flexibility, human data remains largely observational or short-term. The authors' call for mechanistic studies using multi-omics approaches represents the field's next evolution—moving beyond simple weight loss metrics to understand cellular-level changes. Their vision of eventual 'fasting mimetic drugs' highlights a pragmatic reality: even if fasting proves beneficial, long-term dietary restriction remains challenging for most people. This conservative stance may frustrate fasting enthusiasts, but it underscores the scientific rigor needed before declaring any intervention a longevity breakthrough. The template they propose for future studies could finally provide the definitive answers this field desperately needs.